September 23, 2019
FDA: Class I recall of Allergan Natrelle Biocell textured breast implants
Editor's Note
The Food & Drug Administration (FDA) on September 12 designated the recall by Allergan of its Natrelle Biocell textured breast implants as Class I, the most serious.
The recall was initiated because of a six times higher rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system, which has been associated with these implants.
Distribution dates are September 14, 2014, to July 24, 2019.
Free Daily News
- Cluster of mycobacteria infections after total joints traced to OR nurse
- ASA urges public to learn to recognize opioid overdose and how to use naloxone
- Suicide risk screening tools: Clear instructions, staff training recommended for safety, quality
- Telehealth care, MOUD during COVID-19 reduced risk for fatal drug overdoses
- CDC: One bivalent COVID-19 booster is sufficient for now
- Daily step patterns linked to mortality
- UCLA School of Nursing receives grant to attract minorities to doctoral programs
- WHO updates COVID-19 vaccination guidance
- Risk of adverse surgical outcomes in patients with recent COVID-19 infection
- Intentions of nurse leaders to integrate workplace mental health, wellness practices
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity Inclusion & Equity
